When was SynsoryBio founded?

SynsoryBio was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is SynsoryBio located?

SynsoryBio is headquartered in Cambridge, United States.

How many employees does SynsoryBio have?

As of Jun 30, 2026, the latest employee count at SynsoryBio is 2.

Is SynsoryBio a funded company?

SynsoryBio is a funded company, having raised a total of $500K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2024.

When was the latest funding round of SynsoryBio?

SynsoryBio's latest funding was a $***** Grant (prize money) round on Jul 15, 2024, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.53B in funding in 2026 to date.

Where does SynsoryBio rank among its competitors?

SynsoryBio ranks 1808th amongst 3304 active competitors, of which 1117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of SynsoryBio?

SynsoryBio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

SynsoryBio - 2026 Company Profile, Team, Funding & Competitors

SynsoryBio is a seed company based in Cambridge (United States), founded in 2023 by Nathan Tague and Elliot Tague. It operates as a Developer of protein therapeutics for cancer and autoimmune diseases. SynsoryBio has raised $500K in funding from Y Combinator. The company has 3304 active competitors, including 1117 funded and 780 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of protein therapeutics for cancer and autoimmune diseases. The company harnesses the proprietary technology to create next-generation therapeutics, potent drugs and apply to many diseases such as cancer and autoimmune disorders.

Key Metrics

Founded Year

2023

Location

Cambridge, United States

Stage

Seed

Total Funding

$500K in 2 rounds

Latest Funding Round

Grant (prize money), Jul 15, 2024, $*****

Investors

Y Combinator & 1 more

Ranked

1808^th among 3304 active competitors

Employee Count

2 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2984 more

View SynsoryBio's full profile

SynsoryBio has raised a total funding of $500K over 2 rounds. Its first funding round was on 2024. Its latest funding round was a Grant (prize money) round on Jul 15, 2024 for $*****. 1 investor participated in its latest round. SynsoryBio has 2 institutional investors.

Here is the list of recent funding rounds of SynsoryBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2024	1763190	Grant (prize money)	9153855	3918554	1743459	1121615
2024	3709	Seed	2131	6443	Y Combinator	2205

Access funding benchmarks and valuations. Sign up today!

View details of SynsoryBio's funding rounds and investors

The founders of SynsoryBio are Nathan Tague and Elliot Tague.

Here are the details of SynsoryBio's key team members:

Nathan Tague: Co-Founder of SynsoryBio.
Contact Info: 1 email address
Elliot Tague: Co-Founder of SynsoryBio.
Contact Info: 1 email address

View details of SynsoryBio's Founder profiles and Board Members

SynsoryBio's employee count trend

SynsoryBio has 2 employees as of Jun 26. Here is SynsoryBio's employee count trend over the years:

Uncover SynsoryBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SynsoryBio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of SynsoryBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1808th	SynsoryBio 2023, Cambridge (United States), Seed	Developer of protein therapeutics for cancer and autoimmune diseases	$500K	Y Combinator, National Science Foundation	30/100